ReachMD CME
ReachMD
All episodes
Best episodes
Top 10 ReachMD CME Episodes
Goodpods has curated a list of the 10 best ReachMD CME episodes, ranked by the number of listens and likes each episode have garnered from our listeners. If you are listening to ReachMD CME for the first time, there's no better place to start than with one of these standout episodes. If you are a fan of the show, vote for your favorite ReachMD CME episode by adding your comments to the episode page.
09/22/23 • 0 min
Valid until: 22-09-2024
Claim your CME credit at https://reachmd.com/programs/cme/what-is-the-impact-of-first-line-pnh-treatment-choice-on-risk-of-thrombosis/16113/
This program provides awareness for practitioners to correctly diagnose Paroxysmal Nocturnal Hematuria (PNH) due to overlap with other diseases, which often causes a delay in diagnosis. The approval of the first complement inhibitor changed the outlook for people with PNH dramatically, yet today, two-thirds to 80% of patients on anti-C5 therapy still suffer from anemia. Approximately a fourth of patients continue to experience breakthrough hemolysis, a loss of disease control that greatly increases the risk of thrombosis. New treatments are tackling those challenges with different approaches to complement inhibition. This program provides an awareness of managing treatment-related adverse events associated with complement inhibitors. In addition, this program focuses on how healthcare providers can best serve their patients by increasing their confidence in knowing how to discern the differences in new therapeutics available and select the optimal first line regimen best suited for their patients with PNH to increase their quality of life.
09/29/23 • 0 min
Valid until: 29-09-2024
Claim your CME credit at https://reachmd.com/programs/cme/sleep-architecture-and-neurotransmitters-of-sleep/16181/
Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.
Patient Perspective: Living With Insomnia
ReachMD CME
09/29/23 • 0 min
Valid until: 29-09-2024
Claim your CME credit at https://reachmd.com/programs/cme/patient-perspective-living-with-insomnia/16182/
Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.
09/29/23 • 0 min
Valid until: 29-09-2024
Claim your CME credit at https://reachmd.com/programs/cme/exploring-the-impact-of-insomnia-on-daytime-functioning-and-cognition/16183/
Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.
Utilizing Assessment Tools in Insomnia
ReachMD CME
09/29/23 • 0 min
Valid until: 29-09-2024
Claim your CME credit at https://reachmd.com/programs/cme/utilizing-assessment-tools-in-insomnia/16184/
Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.
09/29/23 • 0 min
Valid until: 29-09-2024
Claim your CME credit at https://reachmd.com/programs/cme/examining-treatment-options-for-insomnia-from-orexin-to-gaba/16185/
Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.
09/29/23 • 0 min
Valid until: 29-09-2024
Claim your CME credit at https://reachmd.com/programs/cme/integrating-evidence-and-cultural-sensitivity-in-patient-centric-insomnia-treatments/16186/
Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.
09/22/23 • 0 min
Valid until: 22-09-2024
Claim your CME credit at https://reachmd.com/programs/cme/what-are-the-data-supporting-first-line-c3-inhibitor-treatment-of-pnh/16111/
This program provides awareness for practitioners to correctly diagnose Paroxysmal Nocturnal Hematuria (PNH) due to overlap with other diseases, which often causes a delay in diagnosis. The approval of the first complement inhibitor changed the outlook for people with PNH dramatically, yet today, two-thirds to 80% of patients on anti-C5 therapy still suffer from anemia. Approximately a fourth of patients continue to experience breakthrough hemolysis, a loss of disease control that greatly increases the risk of thrombosis. New treatments are tackling those challenges with different approaches to complement inhibition. This program provides an awareness of managing treatment-related adverse events associated with complement inhibitors. In addition, this program focuses on how healthcare providers can best serve their patients by increasing their confidence in knowing how to discern the differences in new therapeutics available and select the optimal first line regimen best suited for their patients with PNH to increase their quality of life.
09/22/23 • 0 min
Valid until: 22-09-2024
Claim your CME credit at https://reachmd.com/programs/cme/is-long-term-complement-inhibition-safe-and-effective-in-pnh/16114/
This program provides awareness for practitioners to correctly diagnose Paroxysmal Nocturnal Hematuria (PNH) due to overlap with other diseases, which often causes a delay in diagnosis. The approval of the first complement inhibitor changed the outlook for people with PNH dramatically, yet today, two-thirds to 80% of patients on anti-C5 therapy still suffer from anemia. Approximately a fourth of patients continue to experience breakthrough hemolysis, a loss of disease control that greatly increases the risk of thrombosis. New treatments are tackling those challenges with different approaches to complement inhibition. This program provides an awareness of managing treatment-related adverse events associated with complement inhibitors. In addition, this program focuses on how healthcare providers can best serve their patients by increasing their confidence in knowing how to discern the differences in new therapeutics available and select the optimal first line regimen best suited for their patients with PNH to increase their quality of life.
09/22/23 • 0 min
Valid until: 22-09-2024
Claim your CME credit at https://reachmd.com/programs/cme/what-are-the-data-supporting-first-line-c5-inhibitor-treatment-of-pnh/16112/
This program provides awareness for practitioners to correctly diagnose Paroxysmal Nocturnal Hematuria (PNH) due to overlap with other diseases, which often causes a delay in diagnosis. The approval of the first complement inhibitor changed the outlook for people with PNH dramatically, yet today, two-thirds to 80% of patients on anti-C5 therapy still suffer from anemia. Approximately a fourth of patients continue to experience breakthrough hemolysis, a loss of disease control that greatly increases the risk of thrombosis. New treatments are tackling those challenges with different approaches to complement inhibition. This program provides an awareness of managing treatment-related adverse events associated with complement inhibitors. In addition, this program focuses on how healthcare providers can best serve their patients by increasing their confidence in knowing how to discern the differences in new therapeutics available and select the optimal first line regimen best suited for their patients with PNH to increase their quality of life.
Show more best episodes
Show more best episodes
FAQ
How many episodes does ReachMD CME have?
ReachMD CME currently has 1812 episodes available.
What topics does ReachMD CME cover?
The podcast is about Health & Fitness, Medicine, Podcasts and Science.
What is the most popular episode on ReachMD CME?
The episode title 'Expert Answers to Common Questions for Who’s at Risk? Preventing and Managing Tumor Lysis Syndrome and Neutropenia in CLL' is the most popular.
When was the first episode of ReachMD CME?
The first episode of ReachMD CME was released on Dec 14, 2018.
Show more FAQ
Show more FAQ